Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE HYDROCHLORIDE versus PROCHLORPERAZINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE HYDROCHLORIDE versus PROCHLORPERAZINE MALEATE.
FLUPHENAZINE HYDROCHLORIDE vs PROCHLORPERAZINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system; also exhibits anticholinergic, alpha-adrenergic blocking, and extrapyramidal effects.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
2.5-10 mg orally divided every 6-8 hours initially; maintenance 1-5 mg orally daily. For severe psychoses, 2.5-10 mg intramuscularly every 6-8 hours. Maximum oral dose 40 mg/day.
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life 14-24 hours after oral administration; may be longer (up to 48 hours) with chronic use due to accumulation in deep tissues. Clinically, steady state is achieved in 4-7 days.
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
Primarily renal (approximately 50-60% as metabolites, <1% unchanged); fecal (30-40% via biliary elimination); small amount excreted in breast milk.
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic